Epithelial–mesenchymal transition (EMT) is an essential step for tumor progression,
although the mechanisms driving EMT are still not fully understood. In an effort to investigate …

The majority of patients with head and neck squamous cell carcinoma (HNSCC) present
with advanced-stage disease. The current standard of care is surgery followed by adjuvant …

Therapeutic benefits offered by tyrosine kinase inhibitors (TKIs), such as gefitinib (Iressa)
and erlotinib (Tarceva), are limited due to the development of resistance, which contributes …

The epidermal growth factor receptor (EGFR) contributes to the pathogenesis of head&neck
squamous cell carcinoma (HNSCC). However, only a subset of HNSCC patients benefit from …

The∼ 230-residue C-terminal tail of the epidermal growth factor receptor (EGFR) is
phosphorylated upon activation. We examined whether this phosphorylation is affected by …

Resistance to chemotherapy is among the most important issues in the management of
ovarian cancer. Unlike cancer cells, which are heterogeneous as a result of remarkable …

Recurrent human epidermal growth factor receptor 2 (HER2) missense mutations have been
reported in human cancers. These mutations occur primarily in the absence of HER2 gene …

KRAS mutations are a major cause of drug resistance to molecular-targeted therapies.
Aberrant epidermal growth factor receptor (EGFR) signaling may cause dysregulation of …

Neuregulin-1 (NRG-1) and its signaling receptors, erythroblastic leukemia viral oncogene
homologs (ErbB) 2, 3, and 4, have been implicated in both cardiomyocyte development and …

The four members of the ERBB (HER) family of transmembrane receptor tyrosine kinases
are frequently activated in cancer by several mechanisms, such as mutation, amplification …